Abstract

Abstract Amphoterin-induced gene and open reading frame 2 (AMIGO2) has been associated with the prognosis of colorectal, gastric, and cervical cancer. However, its relationship with ovarian cancer remains unclear. This study aimed to clarify the role of AMIGO2 in ovarian cancer. The research involved evaluating AMIGO2 expression in patients with ovarian serous carcinoma using immunohistochemistry. The AMIGO2-high group exhibited significantly shorter progression-free survival (PFS) compared to the AMIGO2-low group. The predictive index of the AMIGO2-high group was considerably higher than that of the AMIGO2-low group. The rate of complete cytoreductive surgery was lower in the AMIGO2-high group than in the AMIGO2-low group. Furthermore, in vitro studies showed that four serous ovarian cancer cell lines expressed AMIGO2 expression and adhesion to mesothelial cells. Adhesion to mesothelial cells was attenuated by AMIGO2 knockdown in SKOV3 cells. Moreover, in a murine model, AMIGO2 downregulation in SKOV3 cells significantly suppressed peritoneal dissemination. These findings suggest that high AMIGO2 expression in serous ovarian carcinoma cells contributes to a poor prognosis by promoting peritoneal metastasis through enhanced cell adhesion to mesothelial cells. Citation Format: Yuki Iida, Shinya Sato, Koji Yamamoto, Kohei Hikino, Masayo Okawa, Masayo Hosokawa, Mayumi Sawada, Hiroaki Komatsu, Akiko Kudoh, Hee Kyung Seong, Runa Izutsu, Mitsuhiko Osaki, Futoshi Okada, Fuminori Taniguchi. AMIGO2 is associated with the peritoneal dissemination in serous ovarian cancer by enhancing its adhesion to peritoneal mesothelial cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1556.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.